HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study

Sęk, Piotr; Żawrocki, Antoni; Biernat, Wojciech; Piekarski, Janusz

doi:10.1111/j.1365-2559.2010.03665.x

Cited by 43 publications

(43 citation statements)

References 41 publications

(96 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 That overrepresentation of HER2 amplification is also found in associated ICB, explaining the more-aggressive behavior of MPD-associated ICB. Most of the cases in our study showed congruent molecular subtypes of MPD and ICB, further underpinning the theory of DCIS-MPD as a precursor lesion to ICB.…”

Section: Associated Lesionsmentioning

confidence: 96%

See 1 more Smart Citation

Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization

Wachter

Fasching

et al. 2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Paget disease of the breast, in most cases, represents intraepidermal spread of ductal carcinoma in situ. Molecular subtypes of invasive carcinoma of the breast have prognostic and therapeutic significance and show characteristic distribution. Little is known about the distribution of molecular subtypes in Paget disease of the breast. Objectives.— To examine the distribution of molecular subtypes in Paget disease of the breast and to compare them to concurrent invasive carcinoma of the breast, if present. Design.— We examined 48 cases of Paget disease of the breast with immunohistochemistry and antibodies against estrogen and progesterone receptors, human epidermal growth factor receptor 2 (HER2), and Ki-67, as well as HER2 chromogenic in situ hybridization, to classify the cases into molecular subtypes. Then, we compared the results to the molecular subtypes of associated invasive carcinoma of the breast, if present. Results.— The HER2 subtype was the most common found in Paget disease of the breast, followed by the luminal B subtype and 2 cases of the triple-negative subtype. The associated invasive carcinoma cases were most often of the luminal B subtype, followed by the HER2 subtype and the triple-negative subtype. The molecular subtype of Paget disease and invasive carcinoma was congruent in most of the cases. Conclusions.— Molecular subtypes of invasive carcinoma of the breast can already be detected in Paget disease. The distribution of molecular subtypes of Paget disease and of Paget disease–associated invasive carcinoma differs from invasive carcinoma without associated Paget disease, with the HER2 subtype overrepresented in Paget disease and associated invasive carcinoma and the luminal and triple-negative subtypes underrepresented.

show abstract

Section: Associated Lesionsmentioning

confidence: 96%

“…In the only other large MPD study that identified MPD molecular subtypes, by Sek et al 12 , no triple-negative cases were found. However, Sek et al 12 described the HER2 subtype in 86% of cases.…”

Section: Associated Lesionsmentioning

confidence: 99%

Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization

Wachter

Fasching

et al. 2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Несмотря на значительный прирост числа вновь выявленных случаев рака МЖ, статистика по РП остается стабильной -0,5-5,0 % от общего числа за-болевших в мире [7][8][9]. Болеют женщины 24-90 лет (средний возраст 50-60 лет) [10,11], преимущественно менопаузального возраста (70 %), хотя выявлены слу-чаи РП и у подростков [12].…”

Section: эпидемиология рака педжетаunclassified

“…В ней пред-полагается малигнизация или дегенерация уже суще-ствующих клеток, а клетки Педжета определяются как злокачественные кератиноциты, возникающие in situ [7][8][9]17].…”

Section: патогенезunclassified

“…Известно, что в большинстве (67-100 %) наблю-дений РП соска сочетается с внутрипротоковой кар-циномой МЖ [9,30,31], но представлены и случаи его сочетания с дольковой карциномой [32]. Изоли-рованное поражение соска встречается реже (7-8 %) [33][34][35].…”

Section: диагностика обзорные статьиunclassified

See 1 more Smart Citation

Paget’s disease of the breast (a review of literature)

Никитина¹,

Нечушкин²,

Trigolosov³

et al. 2016

Tumors of female reproductive system

View full text Add to dashboard Cite

show abstract

Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database

Chen

Yuan

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Background Most mammary Paget disease (MPD) is associated with underlying in situ or invasive breast cancer. The objective of this study was to compare the clinicopathological characteristics and survival outcomes between breast cancer with Paget disease (PD) and breast cancer alone. Methods From the Surveillance, Epidemiology, and End Results (SEER) database, 2000‐2015, of the US National Cancer Institute, we identified 1569 women who had PD with invasive ductal carcinoma (PD‐IDC) and 1489 women who had PD with ductal carcinoma in situ (PD‐DCIS). Independent demographic and clinicopathological variables as well as survival outcomes of these patients were compared to patients with the corresponding breast cancer without concomitant PD. Results PD‐IDC and PD‐DCIS both had worse survival outcomes and poorer tumor characteristics than the corresponding disease without PD. Contrary to in the breast cancer alone groups, in the breast cancer with PD groups, the HR status ( P = 0.182 in PD‐IDC and P = 0.371 in PD‐DCIS), HER2 status ( P = 0.788 in PD‐IDC and P = 0.643 in PD‐DCIS), and combined molecular subtype ( P = 0.196 in PD‐IDC and P = 0.853 in PD‐DCIS) were not found to affect disease prognosis. After matching tumor characteristics and treatment approaches, PD‐IDC as well as PD‐DCIS exhibited no significant difference in disease prognosis with corresponding IDC and DCIS. Finally, by comparative analysis, a kind of PD‐DCIS (ICD‐O‐3 code 8543/3) showed many invasive behaviors (31.8% of 8543/3 patients had stage I‐III cancer) and was associated with worse survival outcomes than the other type of PD‐DCIS. Conclusions Breast cancer with concomitant PD was associated with more aggressive tumor characteristics and worse survival outcomes. The HR status, HER2 status, and combined molecular subtype could not affect the prognosis of breast cancer with PD. Moreover, a portion of the PD‐DCIS cases were invasive breast cancer cases that required special treatment.

show abstract

HER2 molecular subtype is a dominant subtype of mammary Paget’s cells. An immunohistochemical study

Cited by 43 publications

References 41 publications

Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization

Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization

Paget’s disease of the breast (a review of literature)

Comparative study of breast cancer with or without concomitant Paget disease: An analysis of the SEER database

Contact Info

Product

Resources

About